Gardner Denver (GDI) Slammed as SPX (SPW) Talks End
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
UPDATE: Gardner Denver (GDI), SPX Corp (SPW) End Talks; PE May Still Be in Picture
December 21, 2012 2:25 PM EST(Updated - December 21, 2012 3:26 PM EST)
Gardner Denver, Inc. (NYSE: GDI) said to end talks with SPX (NYSE: SPW), private equity talks to resume.
UPDATE - Reuters reports that SPX management came under shareholder... More
SPX (SPW) near $4B deal for Gardner Denver (GDI) - Bloomberg
December 19, 2012 5:28 PM ESTSPX (NYSE: SPW) near $4B deal for Gardner Denver Inc. (NYSE: GDI) - Bloomberg... More
StreetInsider.com Pre-Open Movers 12/19: (ALTE) (VNDA) (GM) Higher; (ONTY) (PLXT) (SYMM) Lower (more...)
December 19, 2012 9:35 AM ESTOncothyreon Inc. (Nasdaq: ONTY) 60% LOWER; announced that the pivotal Phase 3 clinical trial of L-BLP25 (formerly referred to as Stimuvax®) known as START did not meet its primary endpoint of an improvement in overall survival in patients with unresectable, locally advanced stage IIIA or stage IIIB non-small cell lung cancer (NSCLC). The trial was conducted by Merck Serono, a division of Merck KGaA of Darmstadt, Germany, under a license agreement with Oncothyreon.
Alterra Capital Holdings Limited (NASDAQ: ALTE) 20% HIGHER; Markel Corporation... More
